[Skip to Content]
[Skip to Content Landing]
April 13, 1963

The Treatment of Soft-Tissue Sarcoma by Chemotherapy

Author Affiliations

New Orleans

From the Department of Surgery, Tulane University School of Medicine, and Charity Hospital of Louisiana.

JAMA. 1963;184(2):149-152. doi:10.1001/jama.1963.73700150017022b

THE TREATMENT of soft-tissue sarcomas with chemotherapeutic agents has been in progress for over 20 yr. The first effective agent, mechlorethamine hydrochloride (HN2), originally used during World War II, was reported by Gilman and Phillips in 1946.1 These and other observers noted that lymphomas and leukemias often regressed dramatically in response to mechlorethamine hydrochloride, but only about one of ten of the solid cancers responded. In all patients objective improvement was short-lived. In recent years several new agents have been developed which are more effective than mechlorethamine hydrochloride. Among them, meractinomycin has proved useful in the treatment of childhood sarcomas and renal carcinomas2; fluorouracil and idoxuridine in adenocarcinoma of the breast and gastrointestinal tract3; methotrexate in choriocarcinoma of the female4; and vinblastine sulfate in Hodgkin's sarcoma resistant to other chemotherapeutic agents.5

Special techniques have been introduced which have made chemotherapy more effective. Administration

First Page Preview View Large
First page PDF preview
First page PDF preview